KVUE vs PBH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PBH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KVUE and PBH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KVUE and PBH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kenvue is the world's largest pure-play consumer health company, spun off from Johnson & Johnson in 2023. It owns a portfolio of iconic over-the-counter and personal-care brands organized into three segments: Self Care (Tylenol, Motrin, Sudafed, Zyrtec, Benadryl, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX), and Essential Health (Listerine, Band-Aid, Johnson's baby products, Aveeno). Kenvue sells everyday, repeat-purchase health and hygiene products through pharmacies, mass retailers, grocery, and e-commerce in markets around the world. The business makes money by leveraging strong, trusted brands and broad retail distribution to command premium pricing over private label in non-discretionary categories like pain relief, allergy care, oral care, and wound care. Many of its products are recommended by doctors and pharmacists, which reinforces brand loyalty. As a recently independent company, Kenvue is still building out standalone operations and pursuing cost efficiencies, while navigating litigation it inherited from its J&J consumer heritage. Headquartered in Summit, New Jersey.

Full KVUE guide

Prestige Consumer Healthcare Inc. owns over-the-counter healthcare brands rather than inventing them. The portfolio spans Monistat and Summer's Eve in women's health, BC and Goody's pain powders, Clear Eyes and TheraTears eye care, Dramamine, Fleet, Chloraseptic, Luden's, DenTek, Compound W, Nix, Debrox and Boudreaux's Butt Paste, plus Gaviscon in Canada and Hydralyte and the newly acquired Dermal Therapy line in Australia. Most manufacturing is outsourced, so spending goes to advertising and shelf presence instead of factories. Two segments carry the results: North American OTC Healthcare produced about $226 million of the June 2026 quarter's roughly $266 million, and International OTC Healthcare the remaining $40 million. Concentration is real on both ends, with the top five brands at about 39 percent of gross revenue, Walmart at roughly 19 percent and Amazon at roughly 16 percent. The fiscal year ends in March, so the quarter reported on August 6, 2026 was the first of fiscal 2027.

Full PBH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KVUE drivers: Portfolio of trusted, defensive brands; Standalone efficiency and margin upside.
• PBH drivers: The biggest acquisition in years just closed; Organic growth returned, reported gross margin did not.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Kenvue carries significant litigation overhang inherited from its J&J heritage, including high-profile Tylenol and talc-related claims, which create legal and headline risk. For PBH, clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KVUE if you believe its drivers more; PBH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KVUE and PBH guides.

KVUE. Kenvue trades at a consumer-staples multiple, somewhat below larger, faster-growing peers, reflecting its strong brands offset by litigation overhang and an unproven standalone growth track record. The above-average dividend yield is a key anchor for income investors. The valuation embeds expectations of margin improvement and steadier organic growth as the company matures independently and resolves legal uncertainties.

PBH. Fiscal 2026, which ended March 31, 2026, brought revenue of about $1,088.7 million against about $1,137.8 million the year before, so the trailing figure reflects a down year already in the base. The trailing multiple looks undemanding next to consumer staples generally, and the reason is visible on the balance sheet: enterprise value including roughly $2.0 billion of net debt is a very different number from the roughly $2.4 billion equity value. Guidance for fiscal 2027 is not comparable to fiscal 2026 without adjustment, because it now folds in two acquisitions that closed in June and July 2026.

Headline figures (approximate, early 2026): KVUE shows revenue (ttm) ~$15 billion, operating margin ~18%, net income (ttm) ~$1.5 billion, p/e (ttm) ~20x; PBH shows revenue (ttm) ~$1.10B, through the quarter ended June 30, 2026, latest quarter (q1 fy2027) ~$265.7M revenue, up ~6.5%, with ~3.2% organic growth, diluted eps (q1 fy2027) ~$0.61 GAAP and ~$0.98 adjusted, versus ~$0.95 adjusted a year earlier, fiscal 2027 company outlook ~$1,290M to ~$1,315M revenue, ~$4.55 to ~$4.65 adjusted EPS, ~$270M or more adjusted free cash flow.

KVUE and PBH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KVUE and PBH exposure against your real portfolio. It is not an investment adviser.